NCT01437982

A Study to Evaluate the Safety and Efficacy of Lotemax Ophthalmic Suspension 0.5%

A Post Marketing Surveillance to Evaluate the Safety and Efficacy of Lotemax Ophthalmic Suspension 0.5%

• Status: Completed
• Phase: Phase 4
• Study type: Interventional
• Enrollment: 140 (estimated)
• Sponsor: Bausch & Lomb Incorporated · Industry
• Sex: All
• Age: —
• Healthy volunteers: Not accepted

Summary

The objective of this study is to identify any adverse events or adverse drug reactions through post-marketing surveillance under routine clinical practice

Detailed description

The objective of this study is to identify any adverse events or adverse drug reactions through post-marketing surveillance under routine clinical practice after marketing authorization of Lotemax ophthalmic suspension 0.5%

Conditions

• Conjunctivitis, Seasonal Allergic
• Conjunctivitis, Giant Papillary
• Inflammation

Interventions

Type	Name	Description
DRUG	Loteprednol Etabonate	Ocular administration of study drug. at least once within any indication of the label.
DRUG	Prednisolone Acetate 1% Oph Susp	Ocular administration of study drug. at least once within any indication of the label.

Timeline

• Start date: 2010-08-05
• Primary completion: 2015-10-19
• Completion: 2015-10-19
• First posted: 2011-09-21
• Last updated: 2019-11-19

Locations

1 site across 1 country: South Korea